secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069785
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome enters $570M credit facility with Blackstone, retires Hercules loan
--------------------------------------------------------------------------

- New $570M facility includes a $500M term loan (SOFR+4.75%) and a $70M revolver (SOFR+4.00%).
- Initially drew $120M to repay existing Hercules term loan; up to $250M additional draws available at company's option.
- Facility matures May 2030; 60-month interest-only period; expects significant reduction in interest expense.
- Blackstone also purchased $15M of common stock at $107.14 per share in a concurrent private placement.
- Company cites improved cost of capital and expanded credit capacity to support CNS pipeline growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025069785/0000950170-25-069785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025069785/axsm-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer